
In the rapidly evolving landscape of oncology, researchers and investors are often hindered by fragmented data. Triple-Negative Breast Cancer (TNBC) research is currently siloed across disparate sources—including PubMed, ClinicalTrials.gov, patent databases, and news outlets—making manual monitoring slow, expensive, and error-prone. TNBC Insight AI solves this by aggregating, analyzing, and delivering real-time intelligence through a single, unified dashboard. Built on a robust, enterprise-grade architecture using React and a Python/Flask API, our platform leverages OpenAI’s NLP to distill complex publications and trial reports into concise, actionable briefs. The system automates the entire intelligence workflow, allowing users to track drug pipelines, monitor trial enrollment, identify funding signals, and visualize patent landscapes in real-time. By automating these tasks, TNBC Insight AI enables teams to move at the speed of science, ensuring that critical competitive moves and emerging research trends are never missed.
31 May 2026